In STAD, the pathways enriched in the high RMI2 expression group may be related to autoimmune diseases, while the pathways enriched in the low RMI2 expression group are mainly related to neurotrophic and olfactory pathways (Figure 9 and Supplementary Table 12). Here, RMI2 is linked to autoimmune disease.